OCT2 expression in histiocytoses.
H syndrome
Histiocytosis
Mixed histiocytosis
OCT2
Rosai-Dorfman disease
Journal
Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
10
01
2023
accepted:
31
01
2023
revised:
29
01
2023
medline:
10
7
2023
pubmed:
9
2
2023
entrez:
8
2
2023
Statut:
ppublish
Résumé
Diagnosis of histiocytosis can be difficult and one of the biggest challenges is to distinguish between reactive and neoplastic histiocytes on histology alone. Recently, OCT2 nuclear expression was reported in Rosai-Dorfman disease (RDD). Our purpose was to expand the testing of OCT2 on a broader variety of sporadic or H syndrome-related histiocytoses. Cases of histiocytoses were retrieved from the files of Ambroise Paré Pathology Department. All slides and molecular analyses were reviewed, and staining was completed with immunohistochemistry for OCT2. A total of 156 samples from different localizations were tested. Among sporadic cases, 52 patients had RDD, and 10 patients had mixed histiocytosis combining RDD with Erdheim Chester disease (ECD, n = 8), Langerhans cell histiocytosis (LCH, n = 2) or juvenile xanthogranuloma (JXG, n = 1). All these patients were positive for OCT2 in RDD characteristic histiocytes. Twenty-three patients had ECD and all but two (91% - 21/23) were negative for OCT2. By contrast, OCT2 was positive in 11/27 (41%) LCH and 6/16 (38%) JXG. Among the 10 samples of H syndrome-associated histiocytosis, 3 had typical RDD histology, 6 had unclassified histiocytosis, and one had mixed RDD-LCH; all were positive for OCT2. On 16 samples of granulomatous lymphadenitis, OCT2 was negative in epithelioid histiocytes. Our study shows that OCT2 has a sensitivity of 100% for RDD cases and mixed histiocytoses with an RDD component. It is negative in 92% of ECD but expressed in at least 38% of LCH, JXG, and C group histiocytoses. Finally, OCT2 is positive in all H syndrome-related histiocytoses, independent of their histology.
Identifiants
pubmed: 36754897
doi: 10.1007/s00428-023-03508-7
pii: 10.1007/s00428-023-03508-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
81-86Subventions
Organisme : Association Pour la Recherche et L'enseignement en Pathologie
ID : 2022_02
Organisme : Institut National Du Cancer
ID : PRT-K19-143
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Emile JF, Cohen-Aubart F, Collin M et al (2021) Histiocytosis. Lancet 398(10295):157–170
doi: 10.1016/S0140-6736(21)00311-1
pubmed: 33901419
pmcid: 9364113
Durham BH, Lopez Rodrigo E, Picarsic J et al (2019) Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Nat Med 25(12):1839–1842
doi: 10.1038/s41591-019-0653-6
pubmed: 31768065
pmcid: 6898787
Molho-Pessach V, Ramot Y, Camille F et al (2014) H syndrome: the first 79 patients. J Am Acad Dermatol 70(1):80–88
doi: 10.1016/j.jaad.2013.09.019
pubmed: 24172204
Yin L, Xu J, Li M et al (2016) Oct2 and Bob1 are sensitive and specific markers in lineage determination of B cell lymphomas with no expression of conventional B cell markers. Histopathology 69(5):775–783
doi: 10.1111/his.13017
pubmed: 27319306
Liu YZ, Dawson SJ, Latchman DS (1996) Alternative splicing of the Brn-3a and Brn-3b transcription factor RNAs is regulated in neuronal cells. J Mol Neurosci 7(1):77–85
doi: 10.1007/BF02736850
pubmed: 8835784
Ravindran A, Goyal G, Go RS et al (2021) Rosai-Dorfman disease displays a unique monocyte-macrophage phenotype characterized by expression of OCT2. Am J Surg Pathol 45(1):35–44
doi: 10.1097/PAS.0000000000001617
pubmed: 33177341
Kiruthiga KG, Younes S, Natkunam Y (2022) Strong coexpression of transcription factors PU.1 and Oct-2 in Rosai-Dorfman disease. Am J Clin Pathol 158(6):672–677
doi: 10.1093/ajcp/aqac119
pubmed: 36239684
Kemps PG, Picarsic J, Durham BH et al (2022) ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition. Blood 139(2):256–280
doi: 10.1182/blood.2021013338
pubmed: 34727172
pmcid: 8759533
Wang E, Hutchinson CB, Huang Q et al (2010) Histiocytic sarcoma arising in indolent small B-cell lymphoma: report of two cases with molecular/genetic evidence suggestive of a “transdifferentiation” during the clonal evolution. Leuk Lymphoma 51(5):802–812
doi: 10.3109/10428191003699845
pubmed: 20331331
Emile JF, Abla O, Fraitag S et al (2016) Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 127(22):2672–2681
doi: 10.1182/blood-2016-01-690636
pubmed: 26966089
pmcid: 5161007
Morgan NV, Morris MR, Cangul H et al (2010) Mutations in SLC29A3, encoding an equilibrative nucleoside transporter ENT3, cause a familial histiocytosis syndrome (Faisalabad histiocytosis) and familial Rosai-Dorfman disease. PLoS Genet 6(2):e1000833
doi: 10.1371/journal.pgen.1000833
pubmed: 20140240
pmcid: 2816679
Emile JF, Diamond EL, Hélias-Rodzewicz Z et al (2014) Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood 124(19):3016–3019
doi: 10.1182/blood-2014-04-570937
pubmed: 25150293
pmcid: 4224196
Melloul S, Hélias-Rodzewicz Z, Cohen-Aubart F et al (2019) Highly sensitive methods are required to detect mutations in histiocytoses. Haematologica 104(3):e97–e99
doi: 10.3324/haematol.2018.201194
pubmed: 30262559
pmcid: 6395340
Bolze A, Abhyankar A, Grant AV et al (2012) A mild form of SLC29A3 disorder: a frameshift deletion leads to the paradoxical translation of an otherwise noncoding mRNA splice variant. PLoS One 7(1):e29708
doi: 10.1371/journal.pone.0029708
pubmed: 22238637
pmcid: 3251605
Chouk H, Ben Rejeb M, Boussofara L et al (2021) Phenotypic intrafamilial variability including H syndrome and Rosai-Dorfman disease associated with the same c.1088G > A mutation in the SLC29A3 gene. Hum Genomics 15:63
doi: 10.1186/s40246-021-00362-z
pubmed: 34657628
pmcid: 8522101
Doviner V, Maly A, Ne’eman Z et al (2010) H syndrome: recently defined genodermatosis with distinct histologic features. A morphological, histochemical, immunohistochemical, and ultrastructural study of 10 cases. Am J Dermatopathol 32(2):118–28
doi: 10.1097/DAD.0b013e3181b28572
pubmed: 20010285
Razanamahery J, Diamond EL, Cohen-Aubart F et al (2020) Erdheim-Chester disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by MAP2K1. Haematologica 105(1):e5–e8
doi: 10.3324/haematol.2019.216937
pubmed: 31123032
pmcid: 6939531
Latchman DS (1996) The Oct-2 transcription factor. Int J Biochem Cell Biol 28(10):1081–1083
doi: 10.1016/1357-2725(96)00050-7
pubmed: 8930131
Lillycrop KA, Latchman DS (1992) Alternative splicing of the Oct-2 transcription factor RNA is differentially regulated in neuronal cells and B cells and results in protein isoforms with opposite effects on the activity of octamer/TAATGARAT-containing promoters. J Biol Chem 267(35):24960–24965
doi: 10.1016/S0021-9258(19)73991-X
pubmed: 1281152
Lillycrop KA, Estridge JK, Latchman DS (1993) The octamer binding protein Oct-2 inhibits transactivation of the herpes simplex virus immediate-early genes by the virion protein Vmw65. Virology 196(2):888–891
doi: 10.1006/viro.1993.1552
pubmed: 8396817
Fraitag S, Emile JF (2022) Cutaneous histiocytoses in children. Histopathology 80(1):196–215
doi: 10.1111/his.14569
pubmed: 34958507